Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company focused on developing near-patient solutions for critical care, has announced its financial results for the quarter ended June 30, 2025, along with updates on its Symphony IL-6 test program and key operational milestones. The company has initiated patient enrollment in the SYMON-II pivotal clinical trial, which aims to assess the predictive performance of IL-6 levels in ICU patients for 28-day all-cause mortality. Early indicators show continued clinical momentum. Bluejay has amended its license and supply agreement with Toray Industries, extending the timeline to establish alternate cartridge manufacturing to October 2026 and confirming the completion of Toray's know-how transfer and final supply obligations, thereby strengthening Bluejay's manufacturing independence. Additionally, in April 2025, Bluejay raised $3.85 million through a warrant inducement financing. The company anticipates needing additional capital through 2027 to support manufacturing readiness, clinical trials, and regulatory activities and is actively exploring strategic and institutional financing avenues to meet these milestones. Upcoming catalysts for the company include manufacturing site selection and onboarding for cartridge redevelopment, completion of cartridge redevelopment specifications and validation readiness, patient enrollment acceleration and interim data review from SYMON-II, initiation of analytical validation studies, and ongoing partnership and financing discussions to support regulatory strategy. Chief Executive Officer Neil Dey highlighted the continued and timely progress of SYMON-II clinical studies as a major step toward demonstrating the predictive value of Symphony IL-6 in sepsis care.